Search

Displaying results 4251 - 4260 of 7059 in total
  1. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

    Synonyms: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
  2. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  3. Drug

    Temazepam

    go.drugbank.com/drugs/DB00231
    Approved

    Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal … In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to

  4. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  5. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.

  6. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

  7. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. … [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.

  8. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.

    Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.

  10. Drug

    Dimethicone 410

    go.drugbank.com/drugs/DB14005
    Approved

    [L2162] The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. … [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.